

Recommended Immunization Schedule for the Kingdom of Bahrain

| | | CHILDREN | |
|---|---|--|---|
| AGE | | VACCINE | DOSE |
| At birth | | orns born to parents originally from endemic countries. | Single Dose |
|) | Child Hepatitis B for newborns. | | Birth Dose |
| | Diphtheria and Tetanus toxoid with Pertus vaccine (DTaP-Hib-Hep B-IPV) (as Hexava | ssis, Haemophilus Influenzae type b, hepatitis B, Inactivated Polio | 1 st Dose |
| 2 months | Pneumococcal Conjugate (PCV). | nency. | 1 st Dose |
| | Rotavirus vaccine (oral). | | 1 st Dose |
| | | ssis, Haemophilus Influenzae type b, hepatitis B and Inactivated Polio | |
| 4 months | vaccine (DTaP-Hib-Hep B-IPV) (as Hexava | | 2 nd Dose |
| | Oral Polio Vaccine (OPV). | | 2 nd Dose |
| | Pneumococcal Conjugate (PCV). | | 2 nd Dose |
| | Rotavirus vaccine (oral). | | 2 nd Dose |
| 6 months | Diphtheria and Tetanus toxoid with Pertus (DTP-Hib-Hep B) (as Pentavalent). | ssis, Haemophilus Influenzae type b and hepatitis B vaccine | 3 rd Dose |
| | Oral Polio Vaccine (OPV). | | 3 rd Dose |
| | Measles, Mumps, Rubella (MMR). | | 1st Dose |
| 12 months | Varicella (Chickenpox). | | 1 st Dose |
| 15 months | Pneumococcal Conjugate (PCV). | | Booster |
| | Child Hepatitis A. | | 1 st Dose |
| 18 months | Measles, Mumps, Rubella (MMR). | | 2 nd Dose |
| | Tetravalent (DPT, Hib) or Pentavalent (DTF | P-Hib-Hep B) according to availability. | 1 st Booster |
| | Oral Polio Vaccine (OPV). | | 1st Booster |
| | Meningococcal ACWY-135 Conjugate. | | Single Dose |
| 2 years | Child Hepatitis A. | | 2 nd Dose |
| 3 years | Varicella (Chickenpox). | | 2 nd Dose |
| 4-5 years | | ssis vaccine and Inactivated Polio (DTaP-IPV) (as Tetravalent). | 2 nd Booster |
| | Oral Polio Vaccine (OPV). | | 2 nd Booster |
| | Measles, Mumps, Rubella (MMR) if no doc | cument of 2 valid doses of MMR vaccination previously. | Catch up Dose (if not comple |
| | · | ADOLESCENTS | |
| 13 years | Tetanus, diphtheria toxoid, acellular pertu | issis vaccine (Tdap). | Booster |
| 12-13 years | Human Papilloma Virus (HPV) | | 2 Doses (6 months apart |
| | FOR PREVIOUSLY UNIMMUNIS | SED WOMEN AT REPRODUCTIVE AGE GROUP | |
| Tetanus and diphtheria Toxoid (Td) | At first contact Td1. | | Td1 |
| | At least 4 weeks after Td1. | | Td2 |
| | At least 6 months after Td2. | | Td3 |
| | One seem of an Talo | | |
| | One year after Td3. | | Td 1st Booster |
| | One year after Td 1st Booster. | | Td 1 st Booster Td 2 nd Booster |
| Tdap | One year after Td 1st Booster. One dose of Tdap in the second or third to | | |
| | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- | RLY AND HIGH-RISK GROUPS | |
| | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquired introgenic immunosuppression, solid of | RLY AND HIGH-RISK GROUPS risk groups. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom |
| Pneumococcal Conjugate vaccine (PCV) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquired asplenia, congenital or acquired asplenia introgenic immunosuppression, solid of need a second dose 5 years later. | RLY AND HIGH-RISK GROUPS risk groups. years. recommended to at risk groups including (Sickle cell disease/other bleed immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk o | RLY AND HIGH-RISK GROUPS risk groups. years. recommended to at risk groups including (Sickle cell disease/other blacked immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord | risk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic riduals by medications or by disease condition). | ood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years w |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers Other categories at risk to be determined. | risk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic riduals by medications or by disease condition). | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years we chronic renal diseases, chronic renal diseases, chronic and neurodevelopments. |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk oneed a second dose 5 years later. Single dose to individuals at higher risk oneed a second dose 5 years later. Single dose to individuals at higher risk oneed a second dose 5 years later. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incompatic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions, Immune-suppressed individuals at higher risk of the patic diseases, chronic blood disord conditions in the patic disea | risk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic riduals by medications or by disease condition). | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years where the second control of t |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed to Pregnant women, Health care workers. Other categories at risk to be determined Recommended to at risk groups. Two doses single dose to certain high-risk groups. Single dose to certain high-risk groups. Single dose to certain complement cell disease), persistent complement cell disease), persistent complement cell disease of the present | PRLY AND HIGH-RISK GROUPS Trisk groups. years. Trecommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when the original transplant of infection and to elderly above 65 years. Categories at risk of infection including: Iluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). The design of the properties of the properties of the properties and countries and travelers to Holly places, meningitis belt countries and countries are and travelers to Holly places, meningitis belt countries and countries are an attain categories remain at risk of infection such as anatomical or function of the properties of the following conditions: The deficiency and people with HIV infection. The properties of the properti | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the chronic renal diseases, chronic renal |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Varicella vaccine daemophilus Influenza type b vaccine (Hib) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid on need a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers. Other categories at risk to be determined. Recommended to at risk groups. Two doses. Single dose to certain high-risk groups. Booster dose every 5 years given to center cell disease), persistent complement cells. Single dose for >5 years of age having any. Anatomical or functional asplenia (inclination) | risk groups. years. s recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). eed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apart and travelers to Holly places, meningitis belt countries and countries entain categories remain at risk of infection such as anatomical or function of the following conditions: | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the chronic renal diseases, chronic renal |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine Meningococcal ACWY-135 Conjugate vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid on need a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed to Pregnant women, Pregnant women, Health care workers. Other categories at risk to be determined to the categories at risk groups. Two doses single dose to certain high-risk groups. Single dose to severy 5 years given to center cell disease), persistent complement compleme | PRLY AND HIGH-RISK GROUPS Trisk groups. years. Trecommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, material transplant). In addition, certain high-risk people vaccinated when the original transplant of infection and to elderly above 65 years. Categories at risk of infection including: Iluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). The design of the properties of the properties of the properties and countries and travelers to Holly places, meningitis belt countries and countries are and travelers to Holly places, meningitis belt countries and countries are an attain categories remain at risk of infection such as anatomical or function of the properties of the following conditions: The deficiency and people with HIV infection. The properties of the properti | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years we have been also been alignancy and neurodevelopment of the second neurodevelopme |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine laemophilus Influenza type b vaccine (Hib) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid on need a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed to Pregnant women, Pregnant women, Health care workers. Other categories at risk to be determined to the categories at risk groups. Two doses single dose to certain high-risk groups. Single dose to severy 5 years given to center cell disease), persistent complement compleme | PLY AND HIGH-RISK GROUPS Prisk groups. Prisk groups. Precommended to at risk groups including (Sickle cell disease/other blue and immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiency above 65 years. Categories at risk of infection including: Luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). Led by treating physician. Less, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries retain categories remain at risk of infection such as anatomical or function ponent deficiency and people with HIV infection. Let y of the following conditions: Luding sickle cell disease), post bone marrow transplant and certain categories are all disease), post bone marrow transplant and certain categories. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the chronic renal diseases, chronic renal |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine eningococcal ACWY-135 Conjugate vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incompatic diseases, chronic blood disord conditions, Immune-suppressed individed to the pregnant women, Health care workers. Other categories at risk to be determined. Recommended to at risk groups. Two doses. Single dose to certain high-risk groups. Booster dose every 5 years given to centain disease), persistent complement conditions. Anatomical or functional asplenia (inclusive single dose. Single dose. Single dose. Booster doses every 5 years recommended for every season. | PLY AND HIGH-RISK GROUPS Prisk groups. Prisk groups. Precommended to at risk groups including (Sickle cell disease/other blue and immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiency above 65 years. Categories at risk of infection including: Luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). Led by treating physician. Less, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries retain categories remain at risk of infection such as anatomical or function ponent deficiency and people with HIV infection. Let y of the following conditions: Luding sickle cell disease), post bone marrow transplant and certain categories are all disease), post bone marrow transplant and certain categories. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were actional diseases, chroneurologic and neurodevelopment for ≥ 13 years of age. reporting outbreak. ional asplenia (including sick |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incompatic diseases, chronic blood disord conditions, Immune-suppressed individed to the pregnant women, Health care workers. Other categories at risk to be determined. Recommended to at risk groups. Two doses. Single dose to certain high-risk groups. Booster dose every 5 years given to centain disease), persistent complement conditions. Anatomical or functional asplenia (inclusive single dose. Single dose. Single dose. Booster doses every 5 years recommended for every season. | PRLY AND HIGH-RISK GROUPS Prisk groups. years. Be recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when the original syndrome in the certain and to elderly above 65 years. Categories at risk of infection including: Iluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). Beed by treating physician. Bees, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apart and travelers to Holly places, meningitis belt countries and countries entain categories remain at risk of infection such as anatomical or function opponent deficiency and people with HIV infection. By of the following conditions: Unding sickle cell disease), post bone marrow transplant and certain can habits HAJIIS | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the chronic renal diseases, chronic renal |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Seasonal Influenza vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of the Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incompatic diseases, chronic blood disord conditions, Immune-suppressed individed the Pregnant women, Health care workers. Other categories at risk to be determined. Recommended to at risk groups. Two doses. Single dose to certain high-risk groups. Booster dose every 5 years given to center the center of the pregnant of the center of the | RLY AND HIGH-RISK GROUPS risk groups. years. grecommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: lluding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). ed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries entain categories remain at risk of infection such as anatomical or function omponent deficiency and people with HIV infection. y of the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories indeed for hajj pilgrims and certain categories at risk of infection. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphomic younger than age 65 years with the second properties of the second |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Seasonal Influenza vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of the Recommended in every season to certain. Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incompatic diseases, chronic blood disord conditions, Immune-suppressed individed to the Pregnant women, Health care workers. Other categories at risk to be determined. Recommended to at risk groups. Two dos. Single dose to certain high-risk groups. Booster dose every 5 years given to ce cell disease), persistent complement compl | RLY AND HIGH-RISK GROUPS risk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). ed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries retain categories remain at risk of infection such as anatomical or function ponent deficiency and people with HIV infection. y of the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories in the following conditions: uding sickle cell disease). Single dose. | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years where the second properties and neurodevelopment for ≥ 13 years of age. reporting outbreak. ional asplenia (including sick incer after completion of treatments) |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine (Hib) leningococcal ACWY-135 Conjugate vaccine (Seasonal Influenza vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers Other categories at risk to be determined Recommended to at risk groups. Two doses Single dose to certain high-risk groups Booster dose every 5 years given to ceedl disease), persistent complement considered to the complement | PLY AND HIGH-RISK GROUPS Trisk groups. years. Trecommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, elers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). ed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apasterian categories remain at risk of infection such as anatomical or function of the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories remain at categories at risk of infection. OTHER VACCINES Single dose. Single dose (typhoid polysaccharide is repeated after 3 years if indicated in the composition of the | Td 2 nd Booster ood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years where the second properties and neurodevelopment for ≥ 13 years of age. reporting outbreak. ional asplenia (including sick incer after completion of treatments) |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Seasonal Influenza vaccine | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers Other categories at risk to be determined Recommended to at risk groups. Two dos Single dose to certain high-risk groups Booster dose every 5 years given to ce cell disease), persistent complement conditions or functional asplenia (inclusive commended for every season. Yellow Fever Typhoid fever polysaccharide Hepatitis A | PLY AND HIGH-RISK GROUPS Trisk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, elers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). ed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries artain categories remain at risk of infection such as anatomical or function of the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories in the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories at risk of infection. OTHER VACCINES Single dose. Single dose (typhoid polysaccharide is repeated after 3 years if indice 2 doses (if not vaccinated previously). | Td 2 nd Booster cood disorders, congenital or alignancy, leukemia, lymphom younger than age 65 years we have been seen and neurodevelops art for ≥ 13 years of age. reporting outbreak, ional asplenia (including sick moder after completion of treatments). |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine laemophilus Influenza type b vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64 Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers Other categories at risk to be determined Recommended to at risk groups. Two doses Single dose to certain high-risk groups Booster dose every 5 years given to cecell disease), persistent complement considered to the c | RLY AND HIGH-RISK GROUPS risk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, mayorgan transplant). In addition, certain high-risk people vaccinated when of infection and to elderly above 65 years. categories at risk of infection including: luding chronic pulmonary diseases, chronic cardiovascular diseases, clers, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). ed by treating physician. ses, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries entain categories remain at risk of infection such as anatomical or function of the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories in the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories at risk of infection. OTHER VACCINES Single dose (typhoid polysaccharide is repeated after 3 years if indice 2 doses (if not vaccinated previously). Single dose for traveler to certain countries. | Td 2 nd Booster cood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were thronic renal diseases, chronic renal di |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine laemophilus Influenza type b vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) Post exposure prophylaxis (depend on exposure and risk category) Individuals at risk of hepatitis | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk oneed a second dose 5 years later. Single dose to individuals at higher risk oneed a second dose 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions incomplete the patic diseases, chronic blood disord conditions, Immune-suppressed individed Pregnant women, Health care workers Other categories at risk to be determined Recommended to at risk groups. Two doses Single dose to certain high-risk groups Booster dose every 5 years given to cecell disease), persistent complement conditions or functional asplenia (included Single dose). Single dose. Booster doses every 5 years recommended for every season. Yellow Fever Typhoid fever polysaccharide Hepatitis A Meningococcal ACWY-135 Conjugate Oral Polio (OPV)/ Inactivated Polio (IPV) | PLY AND HIGH-RISK GROUPS Trisk groups. years. recommended to at risk groups including (Sickle cell disease/other blaced immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be disease, chronic renal failure, nephrotic syndrome, may be disease transplant). In addition, certain high-risk people vaccinated when the infection and to elderly above 65 years. categories at risk of infection including: dualing chronic pulmonary diseases, chronic cardiovascular diseases, elers, chronic metabolic disorders including diabetes mellitus, chronic reducts by medications or by disease condition). ded by treating physician. des, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apage and travelers to Holly places, meningitis belt countries and countries are categories remain at risk of infection such as anatomical or function omponent deficiency and people with HIV infection. yof the following conditions: uding sickle cell disease), post bone marrow transplant and certain categories in the disease and certain categories at risk of infection. OTHER VACCINES Single dose. Single dose (typhoid polysaccharide is repeated after 3 years if indicated to the province of the province | Td 2 nd Booster cood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the formulated and neurodevelopment of the second properties |
| Pneumococcal Conjugate vaccine (PCV) Pneumococcal Polysaccharide vaccine Tetanus, diphtheria toxoid, acellular pertussis vaccine (Tdap) Seasonal Influenza vaccine Varicella vaccine leningococcal ACWY-135 Conjugate vaccine laemophilus Influenza type b vaccine (Hib) eningococcal ACWY-135 Conjugate vaccine Seasonal Influenza vaccine Travelers (according to travel destination) Post exposure prophylaxis (depend on exposure and risk category) | One year after Td 1st Booster. One dose of Tdap in the second or third to ADULT, ELDE Single dose for adult ≥ 50 years and high- Single dose for adults at age of ≥ 65. Single dose for High-risk, group ≥ 2-64. Single revaccination dose after 5 years acquired asplenia, congenital or acquir iatrogenic immunosuppression, solid oneed a second dose 5 years later. Single dose to individuals at higher risk of Recommended in every season to certain to Children ≥6 months and ≤ 5 years, Adults/elderly ≥ 50 years, Certain chronic medical conditions inchepatic diseases, chronic blood disord conditions, Immune-suppressed individed to Pregnant women, Health care workers Other categories at risk to be determined Recommended to at risk groups. Two doses in Single dose to certain high-risk groups Booster dose every 5 years given to ce cell disease), persistent complement complem | PRLY AND HIGH-RISK GROUPS Trisk groups. Years. Years. Year commended to at risk groups including (Sickle cell disease/other blived immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiencies, chronic renal failure, nephrotic syndrome, may be red immuno-deficiency and to elderly above 65 years. Categories at risk of infection including: Iluding chronic pulmonary diseases, chronic cardiovascular diseases, ders, chronic metabolic disorders including diabetes mellitus, chronic reduals by medications or by disease condition). Bed by treating physician. Bes, 3 months apart from 1 -12 years of age and as 2 doses 4 weeks apases and travelers to Holly places, meningitis belt countries and countries retain categories remain at risk of infection such as anatomical or function ponent deficiency and people with HIV infection. Yof the following conditions: Unding sickle cell disease), post bone marrow transplant and certain categories in the following conditions: Unding sickle cell disease), post bone marrow transplant and certain categories at risk of infection. OTHER VACCINES Single dose. Single dose (typhoid polysaccharide is repeated after 3 years if indicated previously). Single dose for traveler to certain countries. Booster dose for traveler to certain countries. Booster dose for traveler to Polio endemic/ Polio reporting countries. | Td 2 nd Booster cood disorders, congenital or alignancy, leukemia, lymphomy younger than age 65 years were the second and neurodevelops and neurodevelops art for ≥ 13 years of age. reporting outbreak, ional asplenia (including sick encer after completion of treatments). cated). |